UK launches scheme to encourage development of novel antibiotics
The NHS is offering two contracts to pay pharma companies at the start of their research into antibiotics, to promote the development of new antimicrobials.
List view / Grid view
The NHS is offering two contracts to pay pharma companies at the start of their research into antibiotics, to promote the development of new antimicrobials.
A survey of US adults has revealed that the majority are very or somewhat worried that big pharma will take advantage of the COVID-19 pandemic to increase the price of drugs.
Pharma executives are committed to bringing drugs to market to improve the lives of patients but is the industry too introspective to be truly innovative?
Tim Wilsdon and Ryan Lawlor from Charles River Associates explain why price-based procurement strategies can limit the long-term effectiveness and sustainability of vaccine programmes.
Global pharma regulators met to discuss measures to ensure supply continuity, flexible regulatory policies and their expectations for COVID-19 clinical trials.
Mike Owen analyses how smart product information (PIM) management could be crucial in the future of pharma, given how large the industry continues to grow.
The changes could prevent anticompetitive practices between branded and generic pharmaceutical manufacturers, lowering drug prices for consumers.
The huge increase in demand for hand sanitisers since the outbreak of the coronavirus pandemic has seen companies hard-pressed to cope with the logistics.
Research suggests almost 70 percent of global clinical trials have been disrupted by enrolment suspensions caused by the COVID-19 pandemic.
According to a new agreement between Mylan and Gilead, the former has the rights to manufacture and distribute remdesivir in 127 countries, a drug being tested to combat COVID-19.
The US FDA has announced ICU Medical is recalling a lot of Lactated Ringer's Injection due to iron oxide particulates being found by a consumer.
AbbVie and Allergan have announced the Federal Trade Commission has accepted AbbVie's pending acquisition of Allergan for $63 billion.
Amid the disruptions due to COVID-19, companies providing sterile and antiviral packaging solutions look forward to opportunities arising from the concern over viral exposure itself. Regulatory compliance will play a significant role in the rapidly shifting risk terrain.
The EMA's human medicines committee has adopted a positive opinion for eight medicines, recommending their marketing authorisation.
NICE in the UK has announced it will partner with international collaborations to share its work on COVID-19 and develop guidelines for healthcare professionals.